NCT07287098 2026-03-16
preEMBER
Eli Lilly and Company
Phase 2 Not yet recruiting
Clinical Trials
44 trialsNCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT02747004 2026-02-06
Next MONARCH 1
Eli Lilly and Company
Phase 2 Active not recruiting
NCT05161195 2026-02-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
NCT05306340 2026-01-30
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
Phase 3 Active not recruiting
NCT05514054 2026-01-29
EMBER-4
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT07349069 2026-01-22
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3 Not yet recruiting
NCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT03280563 2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2 Completed
NCT06449027 2025-10-01
Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT02333370 2023-06-08
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT05780567 2023-04-21
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT02753686 2023-02-15
Treat ER+ight
Novartis
Completed
NCT05501158 2022-08-19
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Nalagenetics Pte Ltd
Phase NA Unknown
NCT01393990 2020-03-24
A Study of LY2228820 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
NCT02970682 2019-07-12
STEM
Evgen Pharma
Phase 2 Completed
NCT03879174 2019-03-18
Pembro
Mediclinic Middle East
Phase 2 Unknown
NCT01685255 2019-03-11
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Incyte Corporation
Phase 2 Terminated
NCT00728949 2018-06-06
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00847366 2018-03-15
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
AEterna Zentaris
Phase NA Completed
NCT00171704 2017-03-03
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Novartis
Phase 3 Completed
NCT00036270 2015-10-28
TEAM
Pfizer
Phase 3 Completed
NCT00229697 2015-10-05
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
AstraZeneca
Phase 2 Completed
NCT00038467 2014-05-07
IES
Pfizer
Phase 3 Completed
NCT00537771 2013-01-25
HEART
AstraZeneca
Phase 4 Completed
NCT00605267 2012-09-06
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
AstraZeneca
Phase 3 Completed
NCT00241449 2012-06-06
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
AstraZeneca
Phase 3 Completed
NCT00279448 2011-12-23
TEAM
Pfizer
Phase 3 Completed
NCT00152178 2011-07-07
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT00233610 2011-01-27
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00232661 2010-02-03
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
AstraZeneca
Phase 3 Completed
NCT00287534 2009-06-09
ARNO-95
AstraZeneca
Phase 2 Completed
NCT00784862 2009-05-15
ATAC - Pharmacokinetics (PK) Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00286117 2009-05-01
ITA - Clinical Study Comparing ARIMIDEXâ„¢ With NOLVADEXâ„¢ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
AstraZeneca
Phase 3 Completed
NCT00784680 2009-05-01
ATAC - Quality of Life Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00814125 2009-05-01
ATAC - Endometrial Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00784940 2009-04-27
ATAC - Bone Density Sub-Protocol
AstraZeneca
Phase 3 Completed
NCT00034125 2006-07-19
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Eli Lilly and Company
Phase 3 Completed